Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo tili

Onko sinulla jo Inderes-tili?

Cantargia

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
22.9.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that the first patient has been treated in a new arm of the phase Ib clinical trial CIRIFOUR. The new arm adds Cantargia's lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), to the recently established first line therapy for non-small cell lung cancer (NSCLC). Up to 24 non-squamous NSCLC patients will be treated with a combination of nadunolimab, the checkpoint inhibitor Keytruda® (pembrolizumab) and platinum-based chemotherapy. The objective is to assess safety, efficacy, and biomarkers.

Tiedotteet
15.9.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data demonstrating efficacy of its anti-inflammatory IL1RAP-binding antibody CAN10 in an additional model of systemic sclerosis. CAN10 alleviated disease manifestations in this model, which is one of the most commonly used models of the disease. These findings will be presented in an oral presentation at the annual rheumatology conference ACR Convergence, held in Philadelphia, November 10-14, 2022.

Tiedotteet
14.9.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported preclinical data for its lead candidate, the IL1RAP-binding antibody nadunolimab (CAN04), further supporting the promising clinical efficacy seen in pancreatic cancer (PDAC) patients. The new results show that nadunolimab reduces PDAC tumor growth through a strong impact on cancer-associated fibroblasts (CAF), a major component of tumor-supporting stromal cells within PDAC tumors.

Tiedotteet
31.8.
2022

The two main events during and after the second quarter were the positive results from ASCO 2022 and the rights issue. We also discuss Canakinumab's failure in lung cancer and the share's record low market valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

Tiedotteet
31.8.
2022

The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed rights issue (for further information, see the company's press release on 12 August 2022). Through the rights issue, the number of shares and votes in Cantargia increased by 66,795,158. Today, on the last trading day of the month, there are in total 166,987,895 shares and votes in Cantargia.

Tiedotteet
30.8.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported publication of preclinical results demonstrating that Cantargia's lead candidate, the IL1RAP-binding antibody nadunolimab (CAN04), shows synergistic anti-tumor efficacy with chemotherapy through a mechanism likely to be highly relevant in the clinical situation. The effect is dependent on the unique capability of nadunolimab to simultaneously block both the alpha and beta forms of interleukin-1 (IL-1).

Tiedotteet
30.8.
2022

Cantargia AB's ("Cantargia") half year report for the period January until June 2022 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.

Tiedotteet
17.8.
2022

Cantargia AB will publish the company's report for the second quarter for 2022 on Tuesday, August 30, 2022, at 08:30 a.m. CET.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on August 30, at 3:00 p.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the quarterly report for the second quarter 2022, followed by a Q&A-session.

Tiedotteet
12.8.
2022

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE REFER TO "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE.

Tiedotteet
25.7.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data from a collaboration with Johns Hopkins University School of Medicine demonstrating efficacy of CAN10 in a viral myocarditis model. The results highlight the potential of CAN10 in the treatment of this common form of myocarditis ahead of planned clinical trials. The data will be presented in a poster session at one of the world's largest meetings on innovations in cardiac health, the Basic Cardiovascular Sciences (BCVS) Scientific Sessions 2022, being held in Chicago, July 25-28, 2022.

Cantargia